• Lead: Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population

  • Jun 11 2024
  • Duración: 6 m
  • Podcast

Lead: Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population  Por  arte de portada

Lead: Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population

  • Resumen

  • Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population

    Nature Communications

    In this retrospective cohort study of patients receiving medication for treatment of obesity, the authors evaluated the association of semaglutide with incidence of and recurrence of alcohol use disorder (AUD). In the cohort patients received semaglutide or non-GLP1RA medications, including naltrexone and topiramate. In matched cohort analysis, patients who received semaglutide had much lower rates of incident AUD (HR=0.5) compared to those receiving non-GLP1RA medications and in sub-analysis comparing semaglutide to naltrexone/topiramate the also had lower incident AUD (HR=0.44). Among those with a history of AUD, semaglutide was also associated with lower recurrence of AUD (HR=0.44) overall and in sub-analysis (HR=0.25). These findings support potential benefit of semaglutide for AUD in a real-world population and need for randomized clinical trials.

    Read this issue of the ASAM Weekly

    Subscribe to the ASAM Weekly

    Visit ASAM

    Más Menos
activate_primeday_promo_in_buybox_DT

Lo que los oyentes dicen sobre Lead: Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.